{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:46:59Z","timestamp":1789152419238,"version":"build-2803163510"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2008,9,26]],"date-time":"2008-09-26T00:00:00Z","timestamp":1222387200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"DOI":"10.1371\/journal.ppat.1000165","type":"journal-article","created":{"date-parts":[[2008,9,25]],"date-time":"2008-09-25T22:16:26Z","timestamp":1222380986000},"page":"e1000165","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":47,"title":["Substrate Binding Mode and Its Implication on Drug Design for Botulinum Neurotoxin A"],"prefix":"10.1371","volume":"4","author":[{"given":"Desigan","family":"Kumaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Rawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Ashraf","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramanyam","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2008,9,26]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/2338","article-title":"Crystal structure of botulinum neurotoxin type A and implications for toxicity.","volume":"5(10)","author":"DB Lacy","year":"1998","journal-title":"Nat Struct Biol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev.pa.26.040186.002235","article-title":"Molecular pharmacology of botulinum toxin and tetanus toxin.","volume":"26","author":"LL Simpson","year":"1986","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/78005","article-title":"Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B.","volume":"7(8)","author":"S Swaminathan","year":"2000","journal-title":"Nat Struct Biol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/0041-0101(83)90136-8","article-title":"Amino acid composition of Clostridium botulinum type F neurotoxin.","volume":"21(4)","author":"BR DasGupta","year":"1983","journal-title":"Toxicon"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/0041-0101(83)90131-9","article-title":"Purification and amino acid composition of type E botulinum neurotoxin.","volume":"21(4)","author":"BR DasGupta","year":"1983","journal-title":"Toxicon"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"10461","DOI":"10.1016\/S0021-9258(19)85105-0","article-title":"Separation, purification, partial characterization and comparison of the heavy and light chains of botulinum neurotoxin types A, B, and E.","volume":"260(19)","author":"V Sathyamoorthy","year":"1985","journal-title":"J Biol Chem"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0006-291X(85)80009-7","article-title":"Partial amino acid sequences of the heavy and light chains of botulinum neurotoxin type E.","volume":"127(3)","author":"V Sathyamoorthy","year":"1985","journal-title":"Biochem Biophys Res Commun"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0098-2997(94)90043-4","article-title":"Molecular mechanisms of action of bacterial protein toxins.","volume":"15(2)","author":"G Menestrina","year":"1994","journal-title":"Mol Aspects Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2958.1994.tb00396.x","article-title":"Mechanism of action of tetanus and botulinum neurotoxins.","volume":"13(1)","author":"C Montecucco","year":"1994","journal-title":"Mol Microbiol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/1357-4310(96)84845-3","article-title":"Botulinum neurotoxins: mechanism of action and therapeutic applications.","volume":"2(10)","author":"C Montecucco","year":"1996","journal-title":"Mol Med Today"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1348-0421.1995.tb02184.x","article-title":"Structure and function of Clostridium botulinum toxins.","volume":"39(3)","author":"K Oguma","year":"1995","journal-title":"Microbiol Immunol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0300-9084(00)01169-X","article-title":"Identification of the characteristics that underlie botulinum toxin potency: Implications for designing novel drugs.","volume":"82","author":"LL Simpson","year":"2000","journal-title":"Biochemie"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1152\/physrev.2000.80.2.717","article-title":"Neurotoxins affecting neuroexocytosis.","volume":"80(2)","author":"G Schiavo","year":"2000","journal-title":"Physiol Rev"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nature03123","article-title":"Substrate recognition strategy for botulinum neurotoxin serotype A.","volume":"432(7019)","author":"MA Breidenbach","year":"2004","journal-title":"Nature"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1086\/444507","article-title":"Botulism.","volume":"41(8)","author":"J Sobel","year":"2005","journal-title":"Clin Infect Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"18883","DOI":"10.1074\/jbc.M801240200","article-title":"Structure and substrate based inhibitor design for clostridium botulinum neurotoxin serotype A.","volume":"283","author":"D Kumaran","year":"2008","journal-title":"J Biol Chem"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","article-title":"Processing of X-ray diffraction data collected in oscillation mode.","volume":"276","author":"Z Otwinowski","year":"1997","journal-title":"Methods Enzymol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1107\/S0108767390010224","article-title":"Improved methods for building protein models in electron density maps and the location of errors in these models.","volume":"47 (Pt 2)","author":"TA Jones","year":"1991","journal-title":"Acta Crystallogr A"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1107\/S0907444998003254","article-title":"Crystallography & NMR system: A new software suite for macromolecular structure determination.","volume":"54(Pt 5)","author":"AT Brunger","year":"1998","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/nar\/29.1.221","article-title":"PDBsum: summaries and analyses of PDB structures.","volume":"29(1)","author":"RA Laskowski","year":"2001","journal-title":"Nucleic Acids Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.pep.2008.03.010","article-title":"High level expression of the light chain of botulinum neurotoxin serotype C1 and an efficient HPLC assay to monitor its proteolytic activity.","volume":"60","author":"R Rawat","year":"2008","journal-title":"Protein Expr Purif"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/BF01886909","article-title":"Proteolysis of synthetic peptides by type A botulinum neurotoxin.","volume":"14(8)","author":"JJ Schmidt","year":"1995","journal-title":"J Protein Chem"},{"key":"ref23","article-title":"Identification of Residues Surrounding the Active Site of Type A Botulinum Neurotoxin Important for Substrate Recognition and Catalytic Activity.","author":"SA Ahmed","year":"2008","journal-title":"Protein J"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1021\/bi0157969","article-title":"Arg(362) and Tyr(365) of the botulinum neurotoxin type a light chain are involved in transition state stabilization.","volume":"41(6)","author":"T Binz","year":"2002","journal-title":"Biochemistry"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1074\/jbc.M608166200","article-title":"Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons.","volume":"282(7)","author":"JC Burnett","year":"2007","journal-title":"J Biol Chem"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1023\/A:1026386710428","article-title":"Endoproteinase activity of type A botulinum neurotoxin: substrate requirements and activation by serum albumin.","volume":"16(1)","author":"JJ Schmidt","year":"1997","journal-title":"J Protein Chem"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0014-5793(02)03738-9","article-title":"A high-affinity competitive inhibitor of type A botulinum neurotoxin protease activity.","volume":"532(3)","author":"JJ Schmidt","year":"2002","journal-title":"FEBS Lett"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0014-5793(98)01041-2","article-title":"Type A botulinum neurotoxin proteolytic activity: development of competitive inhibitors and implications for substrate specificity at the S1' binding subsite.","volume":"435(1)","author":"JJ Schmidt","year":"1998","journal-title":"FEBS Lett"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"9621","DOI":"10.1074\/jbc.M611211200","article-title":"Mechanism of substrate recognition by botulinum neurotoxin serotype A.","volume":"282(13)","author":"S Chen","year":"2007","journal-title":"J Biol Chem"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.chembiol.2007.03.014","article-title":"Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility.","volume":"14(5)","author":"NR Silvaggi","year":"2007","journal-title":"Chem Biol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.1021\/bi8001067","article-title":"Catalytic Features of the Botulinum Neurotoxin A Light Chain Revealed by High Resolution Structure of an Inhibitory Peptide Complex.","volume":"47","author":"NR Silvaggi","year":"2008","journal-title":"Biochemistry"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1002\/mds.20023","article-title":"Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization.","volume":"19","author":"JD Marks","year":"2004","journal-title":"Mov Disord"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"10906","DOI":"10.1074\/jbc.M513032200","article-title":"Unique substrate recognition by botulinum neurotoxins serotypes A and E.","volume":"281(16)","author":"S Chen","year":"2006","journal-title":"J Biol Chem"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S1093-3263(97)00021-1","article-title":"An extensively modified version of MolScript that includes greatly enhanced coloring capabilities.","volume":"15(2)","author":"RM Esnouf","year":"1997","journal-title":"J Mol Graph Model"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1107\/S0907444998017363","article-title":"Further additions to MolScript version 1.4, including reading and contouring of electron-density maps.","volume":"55(Pt 4)","author":"RM Esnouf","year":"1999","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1107\/S0907444994006396","article-title":"Raster3D Version 2.0. A program for photorealistic molecular graphics.","volume":"50(Pt 6)","author":"EA Merritt","year":"1994","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/protein\/8.2.127","article-title":"LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions.","volume":"8","author":"AC Wallace","year":"1995","journal-title":"Prot Eng"}],"container-title":["PLoS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.ppat.1000165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T04:12:24Z","timestamp":1631851944000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1000165"}},"subtitle":[],"editor":[{"given":"C. Erec","family":"Stebbins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2008,9,26]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2008,9,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1000165","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,26]]}}}